First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Quipt Home Medical: the story is balanced — Medicare reimbursement rate changes for respiratory equipment and oxygen therapy (CMS fee schedule updates typically…
★ Analysts see FY2026 revenue reaching $306M — +24.6% growth in a single year.
What Moves the Stock
1Medicare reimbursement rate changes for respiratory equipment and oxygen therapy (CMS fee schedule updates typically announced in Q4 for following year)
2Same-store patient census growth and patient retention rates in existing markets
3Acquisition announcements and integration execution in fragmented HME market
4Regulatory changes affecting home healthcare delivery models or competitive bidding programs
5Operating margin trajectory and path to sustained profitability given current -1.6% operating margin
6Respiratory equipment rentals and supplies (CPAP machines, oxygen concentrators, nebulizers) - estimated 60-70% of revenue, recurring monthly rental model
7Durable medical equipment sales and rentals (wheelchairs, hospital beds, patient lifts) - estimated 20-25% of revenue
8Sleep apnea diagnostic services and related supplies - estimated 10-15% of revenue
value - The 0.6x price/sales and 5.1x EV/EBITDA multiples attract deep value investors betting on operational turnaround and margin…
Rising interest rates create moderate headwinds through higher financing costs on the 0.85x debt/equity capital structure…
Watch on earnings: CMS Medicare Physician Fee Schedule updates (typically November release) for respiratory equipment reimbursement rates, Monthly active patient census by service line (respiratory vs DME), Adjusted EBITDA margin progression toward industry benchmarks (15-20% for scaled HME providers).
One Sentence Summary:
Quipt Home Medical: the story is balanced — medicare reimbursement rate changes for respiratory equipment and oxygen therapy (cms fee schedule updates typically announced in q4.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.